Cellular Biomedicine Group Inc (NASDAQ:CBMG), saw it’s director, David Bolocan, buy 10,000 shares of common stock at an average price of $5 per share. Following the transaction, started on June 26th and filed July 3rd, Bolocan directly holds a total of 10,000 shares in the company that focuses on developing cell therapies for the treatment of certain degenerative diseases. The Company offers developmental stem cell, progenitor cell, and immune cell projects.
Moreover, Cellular Biomedicine Group Inc (NASDAQ:CBMG) is developing biomedicine based on tissue-derived progenitor cells, embryonic stem (ES) cells and cancer-specific dendritic cells. It considers these cell types as viable options for cell-based therapies to apply to a variety of medical indications.
While no hedge funds are involved with the company yet, other employees of the $109.92 million market cap corporation have made similar moves to Bolocan. Two other insiders have bought over 200,000 shares combined since the May of this year.
Disclosure: The author, Daniel Forstein, holds no positions in any stocks mentioned.
